Leveraging a novel platform technology to develop a first-in-class immunotherapy for Celiac Disease

Project Information

SOMIT

Grant agreement ID: 827234

DOI 10.3030/827234

Project closed

EC signature date 1 August 2018

Start date 1 September 2018

End date 28 February 2019

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost € 71 429,00

EU contribution € 50 000,00

Coordinated by

ALLERO THERAPEUTICS
Belgium